{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:16:58Z","timestamp":1794377818227,"version":"4.9.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejogrb.2025.114836","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:26:31Z","timestamp":1763745991000},"page":"114836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review"],"prefix":"10.1016","volume":"317","author":[{"given":"Laura","family":"Mandal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0294-0562","authenticated-orcid":false,"given":"Louise Udby","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte M\u00f8ller","family":"Luef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Honnens","family":"Tanvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Anne","family":"Vinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejogrb.2025.114836_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/metabo15040260","article-title":"Impact on metabolism generated by surgical and pharmacological interventions for weight loss in women with infertility","volume":"15","author":"Gete Palacios","year":"2025","journal-title":"Metabolites"},{"issue":"6","key":"10.1016\/j.ejogrb.2025.114836_b0010","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0032-1328878","article-title":"Obesity and PCOS: implications for diagnosis and treatment","volume":"30","author":"Legro","year":"2012","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.ejogrb.2025.114836_b0015","unstructured":"Organization WH. Obesity and overweight [Internet]: World Health Organization; 2025 [Updated 2025 May 7, cited 2025 May 22] Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"10.1016\/j.ejogrb.2025.114836_b0020","article-title":"Obesity and its impact on female reproductive health: unraveling the connections","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.ejogrb.2025.114836_b0025","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.2337\/dc11-1150","article-title":"The LiP (lifestyle in pregnancy) study: a randomized controlled trial of lifestyle intervention in 360 obese pregnant women","volume":"34","author":"Vinter","year":"2011","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ejogrb.2025.114836_b0030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejogrb.2025.114836_b0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2147\/CLEP.S456170","article-title":"Semaglutide (Ozempic(\u00ae)) use in Denmark 2018 through 2023 \u2012 user trends and off-label prescribing for weight loss","volume":"16","author":"Mailhac","year":"2024","journal-title":"Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.ejogrb.2025.114836_b0040","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1111\/dom.16291","article-title":"Trends in the use of drugs with weight-loss effect: scandinavian study from 2017 to 2023","volume":"27","author":"Ruiz","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.ejogrb.2025.114836_b0045","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114836_b0050","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.319","article-title":"The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States","volume":"5","author":"Wood","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"issue":"Suppl 2","key":"10.1016\/j.ejogrb.2025.114836_b0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27 Suppl 2","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejogrb.2025.114836_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114836_b0065","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11481-024-10142-w","article-title":"Semaglutide attenuates anxious and depressive-like behaviors and reverses the cognitive impairment in a type 2 diabetes mellitus mouse model via the microbiota-gut-brain axis","volume":"19","author":"de Paiva","year":"2024","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114836_b0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13098-024-01528-0","article-title":"Semaglutide restores astrocyte\u2013vascular interactions and blood\u2013brain barrier integrity in a model of diet-induced metabolic syndrome","volume":"17","author":"Estato","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.ejogrb.2025.114836_b0075","article-title":"Ozempic babies: are weight loss drugs leading to unintended pregnancies?","volume":"388","author":"Nadarajah","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2025.114836_b0080","unstructured":"Agency EM. Wegovy: EPAR - Product Information. European Medicines Agency; 2024."},{"issue":"8","key":"10.1016\/j.ejogrb.2025.114836_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081989","article-title":"Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives","volume":"10","author":"Jensterle","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejogrb.2025.114836_b0090","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2025.114836_b0095","unstructured":"software Csr. Covidence systematic review software. Veritas Health Innovation; 2025."},{"key":"10.1016\/j.ejogrb.2025.114836_b0100","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"9596","key":"10.1016\/j.ejogrb.2025.114836_b0105","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2025.114836_b0110","unstructured":"Wells GA SB, O\u2019Connell D, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2013 [Internet] [cited 2025 March 25] [Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114836_b0115","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/bcp.16354","article-title":"The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: a pharmacovigilance analysis based on the food and drug administration adverse event reporting system","volume":"91","author":"Zhou","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejogrb.2025.114836_b0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1752-1947-7-223","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"7","author":"Gagnier","year":"2013","journal-title":"J Med Case Rep"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114836_b0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","volume":"232","author":"Drummond","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114836_b0130","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/AOG.0000000000005825","article-title":"Role of glucagon-like peptide-1 receptor agonists in people with infertility and pregnancy","volume":"145","author":"Finkle","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114836_b0135","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.ejogrb.2025.114836_b0140","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ekir.2020.02.1027","article-title":"A systematic review and meta-analysis of diabetes during pregnancy and congenital genitourinary abnormalities","volume":"5","author":"Parimi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ejogrb.2025.114836_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067946","article-title":"Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis","volume":"377","author":"Ye","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2025.114836_b0150","article-title":"Semaglutide ameliorates metabolic disorders in offspring via regulation of oocyte ROS of pre-pregnancy obesity mice","author":"Zhang","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ejogrb.2025.114836_b0155","unstructured":"A\/S NN. A Study Investigating Pregnancy Outcomes in Women Exposed to Semaglutide During Pregnancy [Internet] [cited 2025 Jan 5]: ClinicalTrials.gov; 2022 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05503927."},{"key":"10.1016\/j.ejogrb.2025.114836_b0160","unstructured":"A\/S NN. Semaglutide Exposure During Pregnancy: A Non-interventional Post-authorization Safety Study [Internet] [cited 2025 Jan 5]ClinicalTrials.gov; 2023 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT05872022."},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114836_b0165","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijgo.15092","article-title":"Semaglutide and pregnancy","volume":"163","author":"Skov","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114836_b0170","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70021","article-title":"Pregnancy outcomes after semaglutide exposure","volume":"136","author":"Kolding","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.ejogrb.2025.114836_b0175","doi-asserted-by":"crossref","unstructured":"Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. 2020;192(31):E875-e91.","DOI":"10.1503\/cmaj.191707"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114836_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14041197","article-title":"The impact of excessive gestational weight gain on adverse perinatal outcomes: a systematic review","volume":"14","author":"Kalli","year":"2025","journal-title":"J Clin Med"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525011121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525011121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:01:41Z","timestamp":1767096101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211525011121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"alternative-id":["S0301211525011121"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114836","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114836"}}